ストックスクリーナーアプリを入手
0.17
21.52%
-0.04
アフターアワーズ：
.17
Bio Path Holdings Inc (BPTH) 最新ニュース
Marginal Zone Lymphoma Pipeline Appears Robust With 50+ Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail
Procure Space ETF (UFO) Adds Unidentified Aerial Phenomena Risk Disclosure to Prospectus - The Globe and Mail
Bio-Path (NASDAQ:BPTH) Now Covered by Analysts at StockNews.com - Defense World
Bio-Path: Q1 Earnings Snapshot - CT Insider
Bio-Path (NASDAQ:BPTH) Coverage Initiated at StockNews.com - Defense World
Bio-Path (BPTH) to Release Earnings on Wednesday - Defense World
PTC hits Huntington biomarker, but approval path still uncertain - biocentury.com
Small Interfering RNA (siRNA) Therapeutics Market Know the Scope and Trends - openPR.com
StockNews.com Begins Coverage on Bio-Path (NASDAQ:BPTH) - Defense World
Global Chronic Myeloid Leukemia (CML) Treatment Market To Expand At A CAGR Of 7% Reaching $$11.39 Billion B... - WhaTech
Bio-Path (BPTH): Promising Preclinical Results for Obesity Treat - GuruFocus
Bio-Path (BPTH): Promising Preclinical Results for Obesity Treatment | BPTH Stock News - GuruFocus
Bio-Path Holdings Achieves Third Pre-Clinical Milestone Confirming Potential of BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients - The Manila Times
Microbix Presenting at the 2025 Bloom Burton Conference - The Manila Times
Acute Myeloid Leukemia Drugs Market 2034: EMA, PDMA, FDA - openPR.com
Bio-Path Holdings, Inc. to Host Earnings Call - ACCESS Newswire
Cutaneous T-Cell Lymphoma Clinical Trials and Studies 2025: - openPR.com
Cutaneous T-Cell Lymphoma Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
Longleaf Partners Fund Believes PayPal Holdings (PYPL) Has a Compelling Path Forward - Yahoo Finance
StockNews.com Initiates Coverage on Bio-Path (NASDAQ:BPTH) - Defense World
TIBSOVO's Continued Success Solidifies Its Position as a Leader in IDH1 Mutant Space | DelveInsight - The Malaysian Reserve
Indo-Asian News Service - Indo-Asian News Service (IANS)
Acute Myeloid Leukemia Treatment Market 2034: Clinical Trials, - openPR.com
Small Interfering RNA (siRNA) Therapeutics Market Revenue Report with Forecast to 2031 - openPR.com
Bio-Path (NASDAQ:BPTH) Earns Sell Rating from Analysts at StockNews.com - Defense World
What is Roth Capital’s Forecast for Bio-Path Q1 Earnings? - Defense World
Bio-Path Holdings, Inc. (NASDAQ:BPTH) Q2 2024 Earnings Call Transcript - MSN
Bio-Path Holdings Reports 2024 Financial Results and Progress - TipRanks
Bio-Path Holdings Reports Full Year 2024 Financial Results - MarketScreener
Bio-Path Slashes Annual Losses While Breakthrough Obesity Treatment Shows Promise - Stock Titan
Cutaneous T-Cell Lymphoma (CTCL) Treatment Market 2034: Clinical Trials, Medication, Prevalence, Statistics, Revenue, Therapies, EMA, PDMA, FDA Approvals, and Companies by DelveInsight - Barchart
North American Morning Briefing : Tariff Jitters -2- - Marketscreener.com
Small Interfering RNA (siRNA) Therapeutics Market Forecast to Expand with Growing Investment in RNA Therape... - WhaTech
Thyroid Cancer Drugs Market Set For 13% Growth, Reaching $2.2 Billion By 2029 - WhaTech
Antisense Oligonucleotide Therapeutics Market Current Scenario Analysis Report - InsightAce Analytic
North American Morning Briefing : Stock Futures Fall as Focus Shifts From Fed to Tariffs - Marketscreener.com
Bio-Path Holdings Reports Promising Pre-Clinical Results - TipRanks
Bio-Path reports results from preclinical studies of BP1001-A - TipRanks
Bio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients - Marketscreener.com
Breakthrough: Bio-Path's Novel Drug Could Transform Diabetes and Obesity Treatment - Stock Titan
Future-Proofing Growth Non-Viral Drug Delivery Systems - openPR
Bio-Path (NASDAQ:BPTH) Now Covered by StockNews.com - Defense World
Tevogen Bio Holdings Inc. (TVGN) Secures $8M Grant, Accelerates AI Initiatives with Microsoft - Yahoo Finance
1.52%
1.15%
大文字化:
|
ボリューム (24 時間):